Evidence map›Paper›PMID 33808193›Full record

ArticleCancers2021

Increased Pathway Complexity Is a Prognostic Biomarker in Metastatic Castration-Resistant Prostate Cancer.

Bram De Laere, Alessio Crippa, Ashkan Mortezavi, Christophe Ghysel, Prabhakar Rajan, Martin Eklund, Alexander Wyatt, Luc Dirix, Piet Ost, Henrik Grönberg and 2 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.1field-weighted citation impact, top 51% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 8 institutions in 5 countries.

Bram De LaereDepartment of Human Structure and Repair, Ghent University, 9000 Ghent, Belgium.ORCID 0000-0002-1174-0384
Alessio CrippaDepartment of Medical Epidemiology and Biostatistics, Karolinska Institutet, 17177 Stockholm, Sweden.
Ashkan MortezaviDepartment of Medical Epidemiology and Biostatistics, Karolinska Institutet, 17177 Stockholm, Sweden.ORCID 0000-0001-6307-2659
Christophe GhyselDepartment of Urology, AZ Sint-Jan AV Brugge-Oostende, 8000 Brugge, Belgium.
Prabhakar RajanCentre for Molecular Oncology, Barts Cancer Institute, Queen Mary University of London, London E1 4NS, UK.
Martin EklundDepartment of Medical Epidemiology and Biostatistics, Karolinska Institutet, 17177 Stockholm, Sweden.
Alexander WyattDepartment of Urologic Sciences, Vancouver Prostate Centre, University of British Columbia, Vancouver, BC V6H 3Z6, Canada.
Luc DirixDepartment of Oncology, GZA Hospitals Sint-Augustinus, 2610 Antwerp, Belgium.
Piet OstDepartment of Human Structure and Repair, Ghent University, 9000 Ghent, Belgium.
Henrik GrönbergDepartment of Medical Epidemiology and Biostatistics, Karolinska Institutet, 17177 Stockholm, Sweden.
Johan LindbergDepartment of Medical Epidemiology and Biostatistics, Karolinska Institutet, 17177 Stockholm, Sweden.ORCID 0000-0003-3610-6774
On Behalf Of The Core And ProBio Investigators
Karolinska Institutet · SEAZ Sint-Jan · BEGhent University · BEQueen Mary University of London · GBScience for Life Laboratory · SEUniversity Hospital of Basel · CHUniversity of Antwerp · BEUniversity of British Columbia · CA

Funding

Cancerfonden 09-0677Kom op tegen Kanker STI.VLK.2020.0006.01Royal College of Surgeons/Cancer Research UK C19198/A1533Stichting Tegen Kanker C/2014/227Svenska Forskningsrådet Formas K2010-70X-20430-04-3The Erling-Persson family foundation 4-2689-2016
6 · The paper itself

Abstract

Metastatic castration-resistant prostate cancer (mCRPC) is a heterogeneous disease, characterized by common and rare driver gene alterations that provide a selective growth advantage for progressing tumour cells. We hypothesized that the number of distinct gene driver alteration-affected pathways or gene classes was associated with poor prognosis in patients initiating androgen receptor signalling inhibitors (ARSi). We performed a post hoc analysis of an amalgamated baseline circulating tumour DNA (ctDNA) mutational landscape dataset of ARSi-treated men with mCRPC (

Indexed as

biomarkercfDNAmCRPC

Identifiers

PMID33808193
PMCPMC8037684
OpenAlexW3151771386

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.